News & events
Official press releases, product updates, and research insights
Event at
May 15

Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium
Event at
May 15

Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium
Event at
May 15

Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium

New review highlights prognostic and mechanistic roles of secretoneurin in cardiovascular disease

New review highlights prognostic and mechanistic roles of secretoneurin in cardiovascular disease

New review highlights prognostic and mechanistic roles of secretoneurin in cardiovascular disease

Secretoneurin: a potential complementary cardiovascular biomarker

Secretoneurin: a potential complementary cardiovascular biomarker

Secretoneurin: a potential complementary cardiovascular biomarker

Secretoneurin: the next biomarker for cardiovascular disease

Secretoneurin: the next biomarker for cardiovascular disease

Secretoneurin: the next biomarker for cardiovascular disease

Cardinor is acquired by IC Targets AS

Cardinor is acquired by IC Targets AS

Cardinor is acquired by IC Targets AS

CardiNor signs US distribution agreement with IBL-America for the CardiNor Research Use Only Secretoneurin ELISA test

CardiNor signs US distribution agreement with IBL-America for the CardiNor Research Use Only Secretoneurin ELISA test

CardiNor signs US distribution agreement with IBL-America for the CardiNor Research Use Only Secretoneurin ELISA test

CardiNor announces CE marking and launch of new cardiovascular risk marker: The CardiNor Secretoneurin ELISA test

CardiNor announces CE marking and launch of new cardiovascular risk marker: The CardiNor Secretoneurin ELISA test

CardiNor announces CE marking and launch of new cardiovascular risk marker: The CardiNor Secretoneurin ELISA test

CardiNor secures NOK 12 million to commercialise first secretoneurin (SN) ELISA test

CardiNor secures NOK 12 million to commercialise first secretoneurin (SN) ELISA test

CardiNor secures NOK 12 million to commercialise first secretoneurin (SN) ELISA test

CardiNor, Bioventix, Kaivogen, and Akershus University Hospital received €631k in Eurostars funding for Secretoneurin.

CardiNor, Bioventix, Kaivogen, and Akershus University Hospital received €631k in Eurostars funding for Secretoneurin.

CardiNor, Bioventix, Kaivogen, and Akershus University Hospital received €631k in Eurostars funding for Secretoneurin.

New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease

New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease

New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease

Bioventix Invests in CVD Diagnostics Start-up CardiNor

Bioventix Invests in CVD Diagnostics Start-up CardiNor

Bioventix Invests in CVD Diagnostics Start-up CardiNor

CardiNor Receives USD 0.75M to Develop “Missing Link” CV Risk Test

CardiNor Receives USD 0.75M to Develop “Missing Link” CV Risk Test


